By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PsiOxus Therapeutics Limited 

Cherwell Innovation Centre
Unit 77, Heyford Park
Upper Heyford  Oxfordshire  OX25 5HD  United Kingdom
Phone: 44-(0)1869-238069 Fax: 44-(0)1869-238001



Company News
Parker Institute For Cancer Immunotherapy And PsiOxus Announce Intention To Collaborate On Tumor-Specific Immuno-Gene Therapy 4/14/2016 10:27:20 AM
PsiOxus Initiates Combination Of Paclitaxel With Oncolytic Virus Enadenotucirev In Ovarian Cancer Study 3/10/2016 10:32:14 AM
PsiOxus Appoints Dr Paolo Paoletti As Chairman Of The Board 1/7/2016 11:48:00 AM
PsiOxus Initiates Combination Study Of Merck & Co. (MRK)’s Keytruda With Oncolytic Virus Enadenotucirev 12/16/2015 11:09:24 AM
PsiOxus Scores $38.5 Million Series C 5/19/2015 6:04:14 AM
PsiOxus Therapeutics Limited To Present Promising New Data On Novel Oncolytic Immunoncology Platform At American Association for Cancer Research 2015 4/16/2015 1:05:38 PM
PsiOxus Therapeutics Limited Expands Clinical Studies For Immuno-Oncolytic Treatment Following Positive Response To Intravenous Delivery 4/16/2015 10:18:06 AM
PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine 1/13/2015 11:01:11 AM
PsiOxus Therapeutics Limited Select BioOutsource To Support Clinical Sample Analysis For OCTAVE Ovarian Cancer Study 6/19/2014 9:10:34 AM
PsiOxus Therapeutics Limited Initiates "OCTAVE" Ovarian Cancer Study For Oncolytic Vaccine Enadenotucirev 6/17/2014 11:24:18 AM